Altesa BioSciences today announced positive topline results from its Phase 2 placebo-controlled study examining the effects of vapendavir in COPD patients challenged with rhinovirus.  In this study, ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

Gilead Sciences (NasdaqGS:GILD) announced positive data regarding Livdelzi for PBC and bulevirtide for chronic HDV, underscoring progress in liver disease treatment. During the last quarter, the ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company developing new treatments for viral infections in vulnerable populations, today announced the appointment of Katharine Knobil, M.D. as ...

The US regulator has started a priority review of the injectable formulation of HIV-1 capsid inhibitor lenacapavir, which also has breakthrough status, and is due to deliver a decision on the ...

Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...

This makes Lenacapavir significantly more ... Sub-Saharan Africa Leads Global HIV Decline Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS ...